Knight Historical Balance Sheet

GUD Stock

CAD 6.14 0.04 0.66%

Trend analysis of Knight Therapeutics balance sheet accounts such as Net Debt of 3.3 M or Cash of 55.8 M provides information on Knight Therapeutics' total assets, liabilities, and equity, which is the actual value of Knight Therapeutics to its prevalent stockholders. By breaking down trends over time using Knight Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Knight Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Knight Therapeutics is a good buy for the upcoming year.

Knight Therapeutics Inventory

96.43 Million

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Knight Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

About Knight Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Knight Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Knight Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Knight Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Knight currently owns. An asset can also be divided into two categories, current and non-current.

Knight Therapeutics Balance Sheet Chart

Knight Therapeutics Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Knight Therapeutics uses and utilizes its capital. It also shows what exactly a company owns and owes.

At this time, Knight Therapeutics' Retained Earnings are very stable compared to the past year. As of the 17th of May 2024, Accounts Payable is likely to grow to about 89.6 M, while Cash is likely to drop about 55.8 M.

Total Assets Total Stockholder Equity Cash And Short Term Investments Common Stock Total Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of Knight Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Knight Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Knight Therapeutics balance sheet. This account contains Knight Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Knight Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Most accounts from Knight Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Knight Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Knight Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Total Stockholder Equity	842.0M	825.9M	746.9M	823.4M
Total Assets	991.9M	1.1B	945.5M	952.1M

Total Stockholder Equity Total Assets

Knight Therapeutics balance sheet Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Total Current Assets	Common Stock	Other Current Liab	Total Current Liabilities	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Retained Earnings	Accounts Payable	Non Current Assets Total	Other Assets	Net Receivables	Short Term Investments	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Long Term Investments	Property Plant And Equipment Gross
Total Assets		0.96	-0.38	0.51	0.64	0.98	0.93	0.87	0.98	0.4	0.61	0.38	0.64	0.58	0.34	0.59	0.79	0.35	0.65	0.38	0.6	0.4	0.83	0.64	0.91	0.58
Total Stockholder Equity	0.96		-0.53	0.65	0.76	0.98	0.93	0.92	0.99	0.19	0.37	0.54	0.46	0.34	0.55	0.43	0.66	0.19	0.46	0.48	0.44	0.18	0.75	0.41	0.88	0.43
Net Debt	-0.38	-0.53		-0.99	-0.92	-0.44	-0.42	-0.74	-0.5	0.05	0.25	-0.83	0.33	0.29	-0.38	0.45	0.22	-0.13	0.34	-0.62	0.45	0.06	0.08	0.31	-0.34	0.41
Cash	0.51	0.65	-0.99		0.95	0.56	0.53	0.82	0.62	0.02	-0.12	0.81	-0.19	-0.16	0.39	-0.3	-0.07	0.17	-0.19	0.6	-0.3	0.01	0.07	-0.17	0.44	-0.27
Cash And Short Term Investments	0.64	0.76	-0.92	0.95		0.67	0.67	0.91	0.73	0.12	-0.01	0.87	-0.11	-0.06	0.44	-0.22	0.06	0.25	-0.1	0.78	-0.22	0.12	0.19	-0.06	0.64	-0.2
Common Stock Total Equity	0.98	0.98	-0.44	0.56	0.67		0.91	0.87	0.99	0.24	0.47	0.43	0.55	0.46	0.46	0.53	0.75	0.21	0.58	0.38	0.55	0.24	0.84	0.53	0.87	0.54
Common Stock Shares Outstanding	0.93	0.93	-0.42	0.53	0.67	0.91		0.86	0.93	0.35	0.5	0.56	0.53	0.45	0.47	0.44	0.69	0.35	0.5	0.53	0.46	0.34	0.74	0.5	0.97	0.42
Total Current Assets	0.87	0.92	-0.74	0.82	0.91	0.87	0.86		0.91	0.29	0.31	0.72	0.21	0.25	0.4	0.17	0.38	0.31	0.24	0.67	0.18	0.29	0.48	0.28	0.83	0.12
Common Stock	0.98	0.99	-0.5	0.62	0.73	0.99	0.93	0.91		0.26	0.46	0.5	0.51	0.43	0.47	0.47	0.7	0.25	0.53	0.45	0.49	0.26	0.79	0.49	0.89	0.46
Other Current Liab	0.4	0.19	0.05	0.02	0.12	0.24	0.35	0.29	0.26		0.87	-0.06	0.5	0.84	-0.63	0.32	0.39	0.88	0.53	0.18	0.29	1.0	0.22	0.75	0.44	0.27
Total Current Liabilities	0.61	0.37	0.25	-0.12	-0.01	0.47	0.5	0.31	0.46	0.87		-0.25	0.83	0.99	-0.45	0.74	0.76	0.69	0.87	-0.06	0.72	0.87	0.61	0.98	0.54	0.69
Net Tangible Assets	0.38	0.54	-0.83	0.81	0.87	0.43	0.56	0.72	0.5	-0.06	-0.25		-0.36	-0.32	0.56	-0.43	-0.18	0.11	-0.37	0.88	-0.42	-0.07	-0.02	-0.32	0.55	-0.45
Property Plant And Equipment Net	0.64	0.46	0.33	-0.19	-0.11	0.55	0.53	0.21	0.51	0.5	0.83	-0.36		0.86	-0.1	0.85	0.93	0.43	0.94	-0.31	0.87	0.5	0.8	0.89	0.5	0.9
Current Deferred Revenue	0.58	0.34	0.29	-0.16	-0.06	0.46	0.45	0.25	0.43	0.84	0.99	-0.32	0.86		-0.46	0.74	0.78	0.68	0.89	-0.14	0.74	0.84	0.63	0.98	0.49	0.72
Retained Earnings	0.34	0.55	-0.38	0.39	0.44	0.46	0.47	0.4	0.47	-0.63	-0.45	0.56	-0.1	-0.46		-0.05	0.15	-0.49	-0.18	0.38	-0.01	-0.63	0.33	-0.36	0.41	0.01
Accounts Payable	0.59	0.43	0.45	-0.3	-0.22	0.53	0.44	0.17	0.47	0.32	0.74	-0.43	0.85	0.74	-0.05		0.89	0.07	0.92	-0.36	0.99	0.32	0.83	0.84	0.42	0.94
Non Current Assets Total	0.79	0.66	0.22	-0.07	0.06	0.75	0.69	0.38	0.7	0.39	0.76	-0.18	0.93	0.78	0.15	0.89		0.27	0.92	-0.11	0.9	0.39	0.95	0.85	0.68	0.93
Other Assets	0.35	0.19	-0.13	0.17	0.25	0.21	0.35	0.31	0.25	0.88	0.69	0.11	0.43	0.68	-0.49	0.07	0.27		0.36	0.27	0.08	0.88	0.1	0.55	0.43	0.08
Net Receivables	0.65	0.46	0.34	-0.19	-0.1	0.58	0.5	0.24	0.53	0.53	0.87	-0.37	0.94	0.89	-0.18	0.92	0.92	0.36		-0.27	0.91	0.52	0.84	0.95	0.49	0.94
Short Term Investments	0.38	0.48	-0.62	0.6	0.78	0.38	0.53	0.67	0.45	0.18	-0.06	0.88	-0.31	-0.14	0.38	-0.36	-0.11	0.27	-0.27		-0.37	0.17	-0.01	-0.15	0.62	-0.41
Inventory	0.6	0.44	0.45	-0.3	-0.22	0.55	0.46	0.18	0.49	0.29	0.72	-0.42	0.87	0.74	-0.01	0.99	0.9	0.08	0.91	-0.37		0.3	0.84	0.83	0.43	0.92
Other Current Assets	0.4	0.18	0.06	0.01	0.12	0.24	0.34	0.29	0.26	1.0	0.87	-0.07	0.5	0.84	-0.63	0.32	0.39	0.88	0.52	0.17	0.3		0.21	0.75	0.43	0.26
Other Stockholder Equity	0.83	0.75	0.08	0.07	0.19	0.84	0.74	0.48	0.79	0.22	0.61	-0.02	0.8	0.63	0.33	0.83	0.95	0.1	0.84	-0.01	0.84	0.21		0.73	0.7	0.86
Total Liab	0.64	0.41	0.31	-0.17	-0.06	0.53	0.5	0.28	0.49	0.75	0.98	-0.32	0.89	0.98	-0.36	0.84	0.85	0.55	0.95	-0.15	0.83	0.75	0.73		0.53	0.82
Long Term Investments	0.91	0.88	-0.34	0.44	0.64	0.87	0.97	0.83	0.89	0.44	0.54	0.55	0.5	0.49	0.41	0.42	0.68	0.43	0.49	0.62	0.43	0.43	0.7	0.53		0.39
Property Plant And Equipment Gross	0.58	0.43	0.41	-0.27	-0.2	0.54	0.42	0.12	0.46	0.27	0.69	-0.45	0.9	0.72	0.01	0.94	0.93	0.08	0.94	-0.41	0.92	0.26	0.86	0.82	0.39

Click cells to compare fundamentals

Knight Therapeutics Account Relationship Matchups

Knight Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.3B	1.0B	991.9M	1.1B	945.5M	952.1M
Total Stockholder Equity	810.7M	886.2M	842.0M	825.9M	746.9M	823.4M
Net Debt	(107.1M)	(173.4M)	(45.0M)	6.0M	3.1M	3.3M
Cash	169.3M	229.6M	86.0M	71.7M	58.8M	55.8M
Cash And Short Term Investments	430.6M	411.3M	163.0M	191.2M	172.1M	163.5M
Common Stock Total Equity	761.5M	761.8M	723.8M	694.4M	798.5M	616.3M
Common Stock Shares Outstanding	140.1M	132.0M	124.5M	114.9M	101.2M	123.2M
Total Current Assets	698.2M	554.6M	307.3M	395.6M	365.1M	556.5M
Common Stock	723.8M	694.4M	628.9M	599.1M	688.9M	628.1M
Other Current Liab	225.6M	15.9M	11.7M	15.0M	1.0M	993.7K
Total Current Liabilities	350.8M	114.1M	105.3M	141.3M	114.0M	96.9M
Net Tangible Assets	1.0B	549.1M	652.0M	416.3M	374.7M	569.1M
Property Plant And Equipment Net	29.0M	26.2M	29.9M	22.6M	17.9M	14.0M
Current Deferred Revenue	282K	183K	39.9M	14.6M	16.8M	8.9M
Retained Earnings	52.2M	174.5M	191.6M	161.8M	150.9M	178.6M
Accounts Payable	72.8M	44.5M	65.3M	106.1M	85.4M	89.6M
Non Current Assets Total	607.1M	485.0M	684.6M	659.2M	580.4M	435.2M
Other Assets	152.0M	75.5M	57.1M	15.6M	17.9M	17.0M
Net Receivables	111.7M	82.0M	67.4M	110.2M	88.7M	52.7M
Short Term Investments	261.3M	181.7M	77.0M	119.5M	111.4M	174.0M
Liabilities And Stockholders Equity	1.3B	1.0B	991.9M	1.1B	1.2B	1.0B
Inventory	70.9M	56.5M	72.4M	92.5M	91.8M	96.4M
Other Current Assets	85.0M	4.8M	4.5M	1.7M	2.0M	1.9M
Other Stockholder Equity	17.2M	18.8M	21.9M	23.8M	27.3M	15.8M
Total Liab	390.2M	153.4M	149.9M	229.0M	198.6M	130.2M
Long Term Investments	259.7M	174.8M	179.0M	158.0M	120.0M	183.4M
Property Plant And Equipment Gross	29.0M	26.2M	41.0M	56.1M	39.5M	21.3M
Accumulated Other Comprehensive Income	17.4M	(1.5M)	(376K)	41.3M	37.1M	39.0M
Short Term Debt	52.3M	53.6M	28.3M	20.3M	18.2M	17.3M
Intangible Assets	173.4M	156.5M	350.3M	338.8M	290.0M	149.3M
Property Plant Equipment	29.0M	26.2M	29.9M	22.6M	26.0M	13.4M
Other Liab	4.6M	29.6M	36.8M	31.9M	36.7M	38.5M
Non Current Liabilities Total	39.4M	39.4M	44.6M	87.7M	84.6M	88.8M
Non Currrent Assets Other	52.7M	47.3M	47.9M	48.2M	43.4M	70.6M
Long Term Debt Total	9.8M	2.5M	12.7M	57.4M	66.1M	69.4M
Capital Surpluse	16.5M	18.7M	21.8M	23.7M	27.2M	18.3M
Cash And Equivalents	5.3M	2.6M	9.0M	302K	271.8K	258.2K
Net Invested Capital	866.3M	938.0M	877.9M	895.9M	808.7M	732.4M
Net Working Capital	270.7M	438.0M	199.7M	254.3M	251.1M	331.3M
Capital Stock	723.8M	694.4M	628.9M	599.1M	540.0M	526.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Note that the Knight Therapeutics information on this page should be used as a complementary analysis to other Knight Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Knight Stock analysis

When running Knight Therapeutics' price analysis, check to measure Knight Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Knight Therapeutics is operating at the current time. Most of Knight Therapeutics' value examination focuses on studying past and present price action to predict the probability of Knight Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Knight Therapeutics' price. Additionally, you may evaluate how the addition of Knight Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.

Please note, there is a significant difference between Knight Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Knight Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Knight Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Knight Historical Balance Sheet

Knight Therapeutics Inventory

96.43 Million

About Knight Balance Sheet Analysis

Knight Therapeutics Balance Sheet Chart

Total Assets

Total Stockholder Equity

Cash And Short Term Investments

Common Stock Total Equity

Knight Therapeutics balance sheet Correlations

Knight Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Knight Therapeutics balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Knight Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Current Assets	+ 1.0	Other Current Liab
Common Stock	+ 0.99	Total Stockholder Equity
Common Stock	+ 0.99	Common Stock Total Equity
Current Deferred Revenue	+ 0.99	Total Current Liabilities
Inventory	+ 0.99	Accounts Payable
Common Stock Total Equity	+ 0.98	Total Assets

Cash	- 0.99	Net Debt
Cash And Short Term Investments	- 0.92	Net Debt
Net Tangible Assets	- 0.83	Net Debt
Total Current Assets	- 0.74	Net Debt
Other Current Assets	- 0.63	Retained Earnings
Retained Earnings	- 0.63	Other Current Liab